There is a lack of US FDA-approved therapies for non-radiographic axial spondyloarthritis, a deficit that UCB Group hopes to address with its marketed biologic therapy, Cimzia (certolizumab pegol), which is currently indicated for the related condition, ankylosing spondylitis, among a number of other indications.
The Belgium-headquartered multinational reported top-line results from the Phase III C-AXSPAND study on May 16, showing Cimzia met its primary...







